AB Science
AB
Company Profile
Business description
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
Contact
3, Avenue George V
Paris75008
FRAT: +33 147200014
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.80 | 0.10 | 0.00% |
| CAC 40 | 8,349.69 | 2.49 | 0.03% |
| DAX 40 | 25,299.28 | 121.38 | -0.48% |
| Dow JONES (US) | 49,145.31 | 46.68 | -0.09% |
| FTSE 100 | 10,164.92 | 27.57 | 0.27% |
| HKSE | 26,999.81 | 151.34 | 0.56% |
| NASDAQ | 23,518.72 | 191.15 | -0.81% |
| Nikkei 225 | 54,341.23 | 792.07 | 1.48% |
| NZX 50 Index | 13,757.71 | 101.66 | 0.74% |
| S&P 500 | 6,928.56 | 35.18 | -0.51% |
| S&P/ASX 200 | 8,820.60 | 1.20 | -0.01% |
| SSE Composite Index | 4,126.09 | 12.67 | -0.31% |